A revolutionary one-hour procedure may offer relief to those suffering from type 2 diabetes by eliminating the need for daily insulin injections. While insulin injections are an effective method for managing the disease, they can cause discomfort and must be administered regularly based on careful calculations. However, scientists have recently discovered that using mild electric pulses to stimulate the lining of the small intestine can effectively control blood sugar levels, providing a potential alternative to insulin injections.
In a recent clinical trial, 86 percent of type 2 diabetes patients who underwent the procedure were able to manage their condition solely through diet and medication, completely eliminating the need for insulin. Type 2 diabetes, often caused by a poor diet, sedentary lifestyle, and obesity, is characterized by elevated blood sugar levels. It occurs when the body either doesn’t produce enough insulin or becomes resistant to its effects.
High or uncontrolled blood sugar levels over time can lead to organ damage and reduced circulation. Current treatment options, such as the drug metformin and lifestyle changes, can help improve insulin function. However, approximately 25 percent of patients still require daily synthetic insulin injections, which involve calculating the required dose based on their food consumption.
The new procedure, known as ReCET (re-cellularization via electroporation therapy), has the potential to allow insulin-dependent type 2 diabetes patients to discontinue their insulin regimen. The procedure involves delivering electric pulses to the lining of the duodenum, the first part of the small intestine, through an endoscope.
Located just below the stomach, the duodenum is responsible for absorbing most of the nutrients from food. High blood sugar levels are believed to cause changes in the cells lining the duodenum, resulting in insulin resistance. The electric pulses create small holes in these cells, leading to their death and subsequent replacement with healthy new cells that respond properly to the body’s insulin, thereby improving blood sugar control.
In the trial, all 14 patients who underwent the procedure followed a week-long liquid diet to aid in the healing of the gut. They then began taking the diabetes drug semaglutide, which helps regulate insulin release from the pancreas. Typically, semaglutide alone only allows about 20 percent of type 2 diabetes patients to stop insulin use. However, when combined with the ReCET procedure, 86 percent of patients achieved good blood sugar control without insulin. No side effects from the procedure were reported.
Further studies comparing the treatment to a placebo are currently being conducted by researchers from Amsterdam University Medical Center, who presented their findings at the Digestive Disease Week conference earlier this year. It is worth noting that gut procedures have shown promise in treating type 2 diabetes in the past. Gastric bypass surgery, for example, can cure the disease even before patients begin to lose weight by affecting gut hormones responsible for stabilizing blood sugar levels. However, other procedures involving heat have been found to damage the gut lining.
Ahmed R. Ahmed, a bariatric surgeon at Imperial College Healthcare NHS Trust in London, commented on the ReCET procedure, stating that it coupled with medication could replicate the effects of gastric bypass surgery. He added that the duration of the treatment’s benefits would be crucial to its success.
In conclusion, this groundbreaking procedure offers hope to those with type 2 diabetes by potentially eliminating the need for daily insulin injections. By utilizing electrical impulses to rejuvenate the small intestine lining, patients can experience improved blood sugar control and avoid the discomfort and inconvenience of insulin injections. With further research and large-scale studies, this innovative treatment could revolutionize diabetes management and enhance the quality of life for countless individuals living with the disease.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
